Budapest’s Turbine raises €5.5 million to uncover novel cancer therapies with cell simulation and machine learning

Date:

Budapest-based biopharma R&D company, Turbine, has received €5.5 million ($6.7 million) in investment from MassMutual Ventures (MMV) to further develop its machine learning and cell simulation platform for identifying new cancer therapies. The funding comes shortly after previous €20 million funding raised earlier this year. Turbine has also announced the appointment of four independent directors to its board.
Founded in 2015, Turbine’s simulation system can create representations of patient populations that existing biological models cannot, as well as perform assays that would be difficult to achieve otherwise. The company’s closed-loop machine learning process identifies potential treatment targets and validates its simulations in vitro and in vivo assays. The resulting therapy assets have multiple in vivo validations and are often associated with patients with a high unmet need. Supported by drug companies including Bayer and MSD, Turbine now plans to scale up its biology simulation platform to assist with additional partnerships and advance its internal pipeline of simulation-guided programs. 

See also  Improving Postoperative Outcomes in Oncology Patients with Wearable Device Data and Machine Learning

Frequently Asked Questions (FAQs) Related to the Above News

What is Turbine?

Turbine is a Budapest-based biopharma R&D company that specializes in developing machine learning and cell simulation platforms to identify new cancer therapies.

How much investment did Turbine receive from MassMutual Ventures (MMV)?

Turbine received €5.5 million ($6.7 million) in investment from MassMutual Ventures (MMV).

What is Turbine's simulation system capable of doing?

Turbine's simulation system can create representations of patient populations that existing biological models cannot and perform assays that would be difficult to achieve otherwise.

How does Turbine identify potential treatment targets for cancer therapies?

Turbine's closed-loop machine learning process identifies potential treatment targets and validates its simulations in vitro and in vivo assays.

Who are some of the drug companies that support Turbine?

Turbine is supported by drug companies including Bayer and MSD.

What are Turbine's plans for the future?

Turbine plans to scale up its biology simulation platform to assist with additional partnerships and advance its internal pipeline of simulation-guided programs.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Kunal Joshi
Kunal Joshi
Meet Kunal, our insightful writer and manager for the Machine Learning category. Kunal's expertise in machine learning algorithms and applications allows him to provide a deep understanding of this dynamic field. Through his articles, he explores the latest trends, algorithms, and real-world applications of machine learning, making it accessible to all.

Share post:

Subscribe

Popular

More like this
Related

New Nothing Ear Buds Revolutionize Sound Quality and AI Integration

Revolutionize your audio experience with Nothing's new Ear and Ear (a) earbuds, offering premium sound quality and AI integration.

Nothing Launches Highly-Anticipated TWS Earbuds at Unbeatable Prices

Discover Nothing's highly-anticipated TWS Earbuds with ChatGPT integration, exceptional sound quality, and unbeatable prices. Shop now!

DALL-E 2 Sunset: How AI Art Revolution Ended – An Inside Story

Discover the inside story of the end of AI art revolution with DALL-E 2 Sunset. Learn about OpenAI's decision and the impact on artists and tech enthusiasts.

Nvidia vs. Amazon: The AI Stock Showdown

Investors, choose wisely in the AI sector with Nvidia vs. Amazon - find out which company is the more attractively valued stock to capitalize on AI's growth.